loss

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Bluffdale, Dec. 26, 2025 (GLOBE NEWSWIRE) -- As millions of Americans enter the peak weight loss motivation window following the…

3 months ago

What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives

LAKELAND, Dec. 20, 2025 (GLOBE NEWSWIRE) -- This educational analysis is sponsored by Health Journey, a dietary supplement company whose…

3 months ago

Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season

Los Angeles, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Important Information for Readers: This article is for informational purposes only and…

3 months ago

Is SkinnyRx the Best GLP-1 Vendor for 2026? Platform Offers Compounded Semaglutide in Three Forms Starting at $199/Month as New Year Weight Loss Season Approaches

Sacramento, Dec. 18, 2025 (GLOBE NEWSWIRE) -- With the New Year fast approaching and consumer interest in weight loss solutions…

3 months ago

Clinic Secret Unveiled: How This GLP-1 Weight Loss Platform Enables At-Home Access to Ozempic, Semaglutide & Tirzepatide – Clinic Secret

Intro: Clinic Secret Enters the Spotlight as GLP-1 Telehealth Platforms Gain National Attention New York City, NY, Dec. 18, 2025…

3 months ago

Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek

CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company…

4 months ago

South Korea’s Leading Hair Loss Treatment Company, AESMED Co., Ltd., to Participate in Cosmoprof Asia Hong Kong 2025

AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL, South Korea, Oct. 28, 2025 /PRNewswire/ -- AESMED…

5 months ago

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…

5 months ago

DB-OTO Results in theNew England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer…

5 months ago

TrimIQ Weight Loss: Official launched in UK and Ireland With Green Tea Probiotic Complex

New York City, NY, Aug. 02, 2025 (GLOBE NEWSWIRE) -- TrimIQ UK, a pioneering health and wellness brand, proudly announces…

7 months ago